Abrocitinib monotherapy in refractory atopic dermatitis: A case series

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that significantly impairs quality of life. A subset of patients remains refractory to conventional systemic and biologic therapies. In this prospective case series, five patients with moderate-to-severe AD refractory to conventional systemic and biologic therapies received oral abrocitinib 100 mg once daily as monotherapy for 12 weeks. Disease severity and pruritus were assessed using Eczema Area and Severity Index (EASI), Scoring Atopic Dermatitis (SCORAD), and Peak Pruritus Numerical Rating Scale (PP-NRS) at baseline, 4, 8, and 12 weeks. All five patients achieved at least 75% reduction in EASI scores by week 12, with marked decreases in SCORAD and PP-NRS. No serious adverse events occurred; one patient developed hypertriglyceridemia, and one experienced nasopharyngitis. Abrocitinib monotherapy demonstrated rapid and clinically meaningful improvements in disease severity and pruritus with a favorable short-term safety profile in this small cohort of patients with refractory AD. Larger, controlled studies are needed to confirm these findings.